American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Feldman
    Feldman
  3. Voss
    Voss
  4. Sheinfeld
    Sheinfeld
  5. Bajorin
    Bajorin
  6. Bosl
    Bosl
  7. Hakimi
    Hakimi
  8. Carlo
    Carlo
  9. Reuter
    Reuter
  10. Knezevic
    Knezevic

Groups

  1. Department of Medicine (447)
  2. Genitourinary Oncology Service (447)
  3. Solid Tumor Oncology Division (447)
  4. Surgery (109)
  5. Urology (105)
  6. Survivorship Research (93)
  7. Epidemiology and Biostatistics (74)
  8. Biostatistics Service (66)
  9. Department of Pathology and Laboratory Medicine (55)
  10. Weinberg Fellows (55)
Search Within
  1. "Robert Motzer"
Formats
  1. Meeting Abstract (348)
  2. Journal Article (99)
Groups
  1. Department of Medicine (447)
  2. Genitourinary Oncology Service (447)
  3. Solid Tumor Oncology Division (447)
  4. Surgery (109)
  5. Urology (105)
  6. Survivorship Research (93)

More Groups

People
  1. Robert Motzer (447)
  2. Darren Feldman (79)
  3. Martin Voss (78)
  4. George Bosl (75)
  5. Dean Bajorin (65)
  6. Sujata Patil (58)

More People

Years
  1. 2025 (14)
  2. 2024 (16)
  3. 2023 (18)
  4. 2022 (27)
  5. 2021 (24)
  6. 2020 (26)

More Years

Publications
  1. Journal of Clinical Oncology (444)
  2. JCO Precision Oncology (2)
  3. Journal of Oncology Practice (1)

Results (447)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Braun, D. A.; Powles, T.; Gurney, H.; Fong, L.; George, D. J.; Haas, N. B.; McDermott, D. F.; Shuch, B. M.; Meehan, R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605)
    Meeting Abstract

    Shah, N. J.; Bupathi, M.; Garmezy, B.; McKay, R. R.; Ornstein, M. C.; Figlin, R. A.; Picus, J.; Rank, B. H.; Barata, P. C.; Hammers, H. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
    Meeting Abstract

    Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Suárez, C.; Albiges, L.; Beckermann, K.; Hammers, H. J.; Stadler, W. M.; Miller, W. H. Jr; Rojas, C.; Peer, A.; Goh, J. C.; Park, S. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial
    Meeting Abstract

    Grünwald, V.; Keizman, D.; Bedke, J.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; Merchan, J. R.; Eto, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial
    Meeting Abstract

    Motzer, R. J.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Albiges, L.; Suárez, C.; Powles, T.; Motzer, R. J.; Stadler, W. M.; Miller, W. H. Jr; Rojas, C.; Peer, A.; Goh, J. C.; Park, S. H.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313
    Meeting Abstract

    Albiges, L.; Motzer, R. J.; Trevino, S.; Kanesvaran, R.; Centkowski, P.; Reimers, M. A.; Sade, J. P.; Pouessel, D.; Biscaldi, E.; Esteban, E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)
    Meeting Abstract

    McGregor, B. A.; Choueiri, T. K.; Albiges, L.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P. C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save